Novel PTEN mutations in patients with Cowden disease: absence of clear genotype–phenotype correlations

MR Nelen, H Kremer, I Konings, F Schoute… - European Journal of …, 1999 - nature.com
MR Nelen, H Kremer, I Konings, F Schoute, AJ van Essen, R Koch, CG Woods, JP Fryns…
European Journal of Human Genetics, 1999nature.com
Cowden disease (CD) is characterised by multiple hamartomas in a variety of tissues. The
pathological hallmark is the presence of a number of trichilemmomas. Several neurological
symptoms are also part of CD with megalencephaly and Lhermitte-Duclos disease (LDD) as
the most important features. Early recognition of CD patients is important because of the
increased risk of developing malignancies. Breast cancer is the most frequent malignancy,
but also urogenital, digestive tract, and thyroid cancers are found with higher frequencies …
Abstract
Cowden disease (CD) is characterised by multiple hamartomas in a variety of tissues. The pathological hallmark is the presence of a number of trichilemmomas. Several neurological symptoms are also part of CD with megalencephaly and Lhermitte-Duclos disease (LDD) as the most important features. Early recognition of CD patients is important because of the increased risk of developing malignancies. Breast cancer is the most frequent malignancy, but also urogenital, digestive tract, and thyroid cancers are found with higher frequencies. CD was localised to chromosome 10q23 and the PTEN gene (also known as MMAC1 or TEP1) was shown to be involved. Germline mutations were identified in both familial and sporadic CD patients. We identified eight PTEN mutations, of which seven were novel, in 13 CD patients. Combined with previous data we have identified 17 independent CD mutations. Gross DNA alterations in CD patients were not detected. Genotype–phenotype relations are discussed. The only correlation suggested to exist is that missense mutations are not detected in LDD patients. However, larger numbers are needed to confirm this. Association of PTEN mutations and the occurrence of malignant breast disease found in an earlier study cannot be confirmed. Clinical features of five CD patients without a PTEN mutation in the coding sequence do not differ from CD patients with a PTEN mutation. Furthermore, it is likely that we have identified the majority of CD patients in the Netherlands. From this we estimate that CD has a prevalence of about 1 in 250 000 in the Dutch population with a low mutation frequency.
nature.com